The 2019 novel coronavirus disease (COVID-19), which is caused by the novel beta coronavirus, SARS-CoV-2, is currently prevalent all over the world, causing thousands of deaths with relatively high virulence. Like two other notable beta coronaviruses, severe acute respiratory syndrome coronavirus-1 (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 can lead to severe contagious respiratory disease. Due to impaired cellular immunity and physiological changes, pregnant women are susceptible to respiratory disease and are more likely to develop severe pneumonia. Given the prevalence of COVID-19, it is speculated that some pregnant women have already been infected. However, limited data are available for the clinical course and management of COVID-19 in pregnancy. Therefore, we conducted this review to identify strategies for the obstetric management of COVID-19. We compared the clinical course and outcomes of COVID-19, SARS, and MERS in pregnancy and discussed several drugs for the treatment of COVID-19 in pregnancy.
【저자키워드】 COVID-19, antiviral drug, Severe acute respiratory syndrome, vertical transmission, Middle East respiratory syndrome, Obstetric management, Perinatal outcome, 【초록키워드】 Treatment, SARS-CoV-2, drug, outcome, MERS, SARS-CoV-1, MERS-CoV, pregnant women, 2019 novel coronavirus, Clinical course, Pregnancy, management, Respiratory disease, death, severe pneumonia, virulence, disease, Obstetric, Middle East, Impaired Cellular Immunity, Beta coronaviruses, acute respiratory syndrome, respiratory syndrome coronavirus, contagious, Physiological changes, beta coronavirus, susceptible, prevalent, identify, develop, caused, conducted, Like, notable, prevalence of COVID-19,